Login to Your Account

NLS phase II results advance effort for alternative ADHD drug niche

By Michael Fitzhugh
Staff Writer

Wednesday, May 31, 2017

NLS Pharma Group’s lead compound, NLS-1 (mazindol), more than halved a common measure of attention deficit hyperactivity disorder (ADHD) symptoms in 55 percent of treated adults vs. 15.8 percent of placebo-treated subjects in a randomized phase II trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription